Boehringer Ingelheim has revealed that survodutide (BI 456906) has received the Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Halia Therapeutics revealed the initial dosing of HT-4253, an innovative oral LRRK2 inhibitor aimed at reducing neuroinflammation in Alzheimer's, in a healthy participant.

MediLink Therapeutics announced a partnership for a global clinical trial and a supply agreement with Amgen Inc. Under this agreement.

Oct 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

TiumBio announced that it has administered the first dose to a patient in its Phase 2 clinical study of TU2218.

Oct 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Kezar Life Sciences were informed that the IND application for zetomipzomib, intended for lupus nephritis (LN) treatment, has been put on clinical hold.

Eton Pharmaceuticals revealed that it has engaged in an asset purchase deal to obtain Increlex® (mecasermin injection) from Ipsen S.A.

Theriva™ Biologics Reports Favorable Results in Phase 1b/2a Trial of SYN-004 (ribaxamase) for Allogeneic Hematopoietic Cell Transplant Patients.

ABL Bio, revealed that it has formed a clinical trial collaboration and supply agreement with MSD.

Alentis Therapeutics gains FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting the treatment of squamous cell cancers.

The FDA has authorized the use of Opdivo® (nivolumab) with chemotherapy before surgery and as a post-surgery treatment for resectable NSCLC.